We want to establish a new drug discovery platform technology for protein-protein interaction (PPI) inhibitors which were regarded until now as undruggable targets. We are currently based in Martinsried in Germany. We would like to create a new company in the US. We are seeking $0,5 M seed for the proof-of-concept study demonstrating efficacy of an anti-cancerous Myc-inhibitor in mice. We were so far awarded 2 grants for this project.